Biogenerics Limited Listed on Frankfurt Stock Exchange


TYLER, Texas, Aug. 2, 2006 (PRIMEZONE) -- The Board of Directors of Biogenerics Ltd. (Pink Sheets:BIGN) is pleased to announce that it has been listed on the Frankfurt Exchange in Frankfurt, Germany. The symbol assigned to the Company is


               Symbol: D9G 
               ISIN: US09063F1012 
               WKN: A0HG80.

The Company chose the Frankfurt Stock Exchange as a result of a growing interest from European investors who make up an already existing foreign shareholder base. The listing in Frankfurt will provide a more liquid market to those existing shareholders as well as make the Company more visible and accessible to new share holders.

The Frankfurt Stock Exchange is one of the biggest and most efficient exchanges in the world. It has over a 90 percent turnover in the German market and a big share in the European market.

For more information, visit our website at http://www.bignltd.com

About Biogenerics Limited

Biogenerics is a diversified investment venture capital firm focused on exploiting and distributing domestic oil and gas reserves. Biogenerics also has joint venture activities with Tyche Energy and Hydroslotter Corporation.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.


            

Contact Data